08.09.2016 • NewsDede WillamsBayerInvestor

Bayer Investor Calls new Monsanto Bid “too Generous”

(c) Zadorozhnyi Viktor/Shutterstock
(c) Zadorozhnyi Viktor/Shutterstock

An unnamed top-30 investor in Bayer has called the German group’s enhanced $127.50 per share revised offer for Monsanto, aimed at securing a deal to buy U.S. rival Monsanto, “far too generous.” The investor told the news agency Reuters that the sweetened bid “would represent a “heavily overpaid” takeover, should it proceed.

The latest comment echoes concerns expressed earlier by top-level Bayer shareholders to the deal that under current terms would be worth more than $65 billion. Both the strategic rationale and the valuation have been questioned.

At the same time, the investor said it was relieved that Bayer did not seem prepared to offer $135-$145 per share, as some analysts estimate the group could have to pay to clinch a deal. In this case, it said, Bayer would need more equity, which require shareholder approval, and this would not be forthcoming.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.